ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells

Despite new agent development and short-term benefits in patients with colorectal cancer (CRC), metastatic CRC cure rates have not improved due to high rates of 5-fluorouracil (5-FU)/leucovorin/oxaliplatin (FOLFOX)-resistance and a clinical therapeutic plateau. At the same time, this treatment regim...

Descripción completa

Detalles Bibliográficos
Autores principales: Narayan, Satya, Ramisetti, Srinivasa, Jaiswal, Aruna S., Law, Brian K., Singh-Pillay, Ashona, Singh, Parvesh, Amin, Shantu, Sharma, Arun K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115410/
https://www.ncbi.nlm.nih.gov/pubmed/30384048
http://dx.doi.org/10.1016/j.ejmech.2018.10.052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115410/
https://www.ncbi.nlm.nih.gov/pubmed/30384048
http://dx.doi.org/10.1016/j.ejmech.2018.10.052

Ejemplares similares